Erlotinib in Patients With Resected, Early Stage NSCLC With Confirmed Mutations in the EGFR
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00567359|
Recruitment Status : Completed
First Posted : December 4, 2007
Results First Posted : December 11, 2018
Last Update Posted : December 11, 2018
- Study Details
- Tabular View
- Study Results
- How to Read a Study Record
In this research study erlotinib will be given to eligible participants whose lung cancer has been removed by surgery. Eligible patients have adenocarcinoma, a type of non-small lung cancer, and must have 1 or more of the following characteristics: be female, be of Asian or Pacific Rim descent and/or be a never smoker. The potential participant's tumor will be examined for Epidermal growth factor (EGFR) mutations. EGFR is a protein that is overexpressed in most non-small cell lung cancers. Some EGFR has been found to have specific mutations and the participant must have one of these mutations in his tumor.
Erlotinib blocks this protein and may control tumor growth and increase survival. Previous research has shown that erlotinib is most effective for people who have these specific mutations in the EGFR.
|Condition or disease||Intervention/treatment||Phase|
|Non-small Cell Lung Cancer||Drug: Erlotinib||Phase 2|
- Erlotinib is a pill taken daily and participants may continue to receive erlotinib for up to two years, as long as the cancer does not return and they do not experience any unacceptable side effects.
- While participants are receiving erlotinib, they will be asked to return to the clinic for study visits to monitor the status of their disease and their general health. For the first 5 months of erlotinib, they will return to the clinic monthly. After that they will return to the clinic every three months.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||100 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase II Trial of Adjuvant Erlotinib in Patients With Resected, Early Stage Non-Small Cell Lung Cancer (NSCLC) With Confirmed Mutations in the Epidermal Growth Factor Receptor (EGFR)|
|Study Start Date :||December 2007|
|Actual Primary Completion Date :||December 2017|
|Actual Study Completion Date :||December 2017|
Oral drug taken daily around the same time. Starting dose is 150mg once daily.
Other Name: Tarceva
- 2-year Disease-free Survival [ Time Frame: 2 years ]The number of participants alive and free from disease recurrence 2 years after enrollment. Participants were monitored for disease recurrence with the use of surveillance radiographs. When possible and medically appropriate, tissue biopsies were obtained to prove recurrence.
- Number of Participants With Treat Related Serious Adverse Events [ Time Frame: From the start of treatment until 30 days after the end of treatment, up 13 months total ]Adverse events were assessed using Common Terminology Criteria for Adverse Events (CTCAE 3.0) from the start of treatment until 30 days after the end of treatment. Serious adverse events were defined as adverse events that were grade 3 or greater and deemed to be possibly, probably or definitely related to the study treatment.
- Median Overall Survival [ Time Frame: From the time of registration until death, up to approximately 9 years ]The median amount of time from the time of registration until death due to any cause
- Median Disease Free Survival [ Time Frame: From registration to disease recurrence or death, up to approximately 9 years ]The median amount of time measured from the time of registration until the time of disease recurrence or death.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Pathologically confirmed diagnosis of NSCLC of adenocarcinoma histology
- Stage IA-B, IIA-B, or IIIA by the American Joint Committee on Cancer 7th edition staging criteria
- Patients must have undergone surgical resection with curative intent within 6 months of enrollment
- Sufficient tumor tissue available for EGFR mutation analysis
- At least ONE of the following patient characteristics: previously detected deletion 19 or L858R EGFR mutation, female sex, history of never smoking, or Asian/Pacific Rim ethnicity (to be enrolled in the screening portion of trial).
- 18 years of age or older
- Tumor samples must have either exon 19 deletion mutations or the exon 21 L858R point mutation
- ECOG Performance status of 0,1, or 2
- Adequate organ function as outlined in protocol
- Radiographic evidence of recurrent NSCLC prior to erlotinib treatment
- Confirmed T790M resistance mutation in the primary tumor sample
- Prior exposure to EGFR tyrosine kinase inhibitors
- Known hypersensitivity to erlotinib, gefitinib, or any closely related drug
- Pregnant or breastfeeding women
- Any evidence of clinically active interstitial lung disease
- Current use of enzyme-inducing anti-epileptic drugs, including carbamazepine, oxcarbazepine, phenytoin, fosphenytoin, phenobarbital, and primidone
- Evidence of any other significant clinical disorder or laboratory finding that makes it undesirable for the patient to participate in the study
- Use of any non-FDA approved or investigational agent within 2 weeks of enrolling onto the trial, or failure to recover from the side effects of any of these agents
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00567359
|United States, California|
|Stanford, California, United States, 94305|
|United States, Massachusetts|
|Massachusetts General Hosptial|
|Boston, Massachusetts, United States, 02114|
|Beth Israel Deaconess Medical Center|
|Boston, Massachusetts, United States, 02115|
|Dana-Farber Cancer Institute|
|Boston, Massachusetts, United States, 02115|
|North Shore Medical Center|
|Peabody, Massachusetts, United States, 01960|
|United States, Missouri|
|Washington University School of Medicine|
|Saint Louis, Missouri, United States, 63110|
|United States, New York|
|Memorial Sloan Kettering Cancer Center|
|New York, New York, United States, 10021|
|United States, Ohio|
|Taussig Cancer Center|
|Cleveland, Ohio, United States, 44195|
|Principal Investigator:||Lecia V. Sequist, MD, MPH||Massachusetts General Hospital|
Documents provided by Lecia V. Sequist, Massachusetts General Hospital:
|Responsible Party:||Lecia V. Sequist, Principal Investigator, Massachusetts General Hospital|
|Other Study ID Numbers:||
|First Posted:||December 4, 2007 Key Record Dates|
|Results First Posted:||December 11, 2018|
|Last Update Posted:||December 11, 2018|
|Last Verified:||November 2018|
epidermal growth factor receptor
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Neoplasms by Site
Respiratory Tract Diseases
Protein Kinase Inhibitors
Molecular Mechanisms of Pharmacological Action